Physician Resources

More detailed information on TTX and WEX’s clinical trials can be found in the document below “A Clinician’s Guide to TTX.”

For additional queries, please contact:

Walter Korz
Vice President, General Manager
(604) 676-7893
walterk@wexpharma.com

A Clinician’s Guide to TTX, click here to download the PDF (94 KB)

CLINICAL TRIALS

Dedicated to the Discovery, Development, Manufacture, and Commercialization of innovative drug products to treat local and systemic pain. TEC-006 - A clinical trial for the treatment of moderate to severe inadequately controlled cancer-related pain. TTX-CINP-201 - A clinical trial for the treatment of moderate to severe neuropathic pain caused by chemotherapy in patients with cancer. TTX-CINP-201 trial featured on NBC-2 news in Port Charlotte Florida.

Dedicated to the Discovery, Development, Manufacture, and Commercialization of innovative drug products to treat local and systemic pain.

TEC-006 - A clinical trial for the treatment of moderate to severe inadequately controlled cancer-related pain.

TTX-CINP-201 - A clinical trial for the treatment of moderate to severe neuropathic pain caused by chemotherapy in patients with cancer.

TTX-CINP-201 trial featured on NBC-2 news in Port Charlotte Florida.

MEMBER OF:

CK Life Sciences Int'l.,(Holdings) Inc. (0775.HK) is engaged in research, development and commercialisation of innovative biotechnology products applicable to human health and environmental sustainability.